Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 3/20 | 0.37 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.37 |
| ▸ | TGM2 | P21980 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3048332 | 0.93 | HDAC1 (0.39) | HDAC1HDAC8 | |
| SCHEMBL3048338 | 0.93 | HDAC1 (0.39) | HDAC1HDAC8 | |
| SCHEMBL7859864 | 0.88 | HDAC1 (0.35) | HDAC1HDAC8 | |
| SCHEMBL8200178 | 0.88 | CYP3A4 (0.47) | — | |
| SCHEMBL7870804 | 0.88 | HDAC1 (0.35) | HDAC1HDAC8 | |
| SCHEMBL635652 | 0.86 | HDAC1 (0.40) | HDAC1HDAC8TGM2 | |
| SCHEMBL635651 | 0.86 | HDAC1 (0.40) | HDAC1HDAC8TGM2 | |
| SCHEMBL636028 | 0.85 | HDAC1 (0.39) | HDAC1HDAC8TGM2 | |
| SCHEMBL636026 | 0.85 | HDAC1 (0.39) | HDAC1HDAC8TGM2 | |
| SCHEMBL636027 | 0.85 | HDAC1 (0.39) | HDAC1HDAC8TGM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2086980-B1 | MACROCYCLIC PEPTIDES AS HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2010-12-22 | — | — | EP | disclosed |
| US-7763584-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-07-27 | — | — | US | disclosed |
| US-7763584-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-07-27 | — | — | US | disclosed |
| US-20080145334-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2008-06-19 | — | — | US | disclosed |
| US-20080145334-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2008-06-19 | — | — | US | disclosed |
| WO-2008064061-A1 | MACROCYCLIC PEPTIDES AS HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080145334-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, HCCS, VIP | HDAC1 2500/4885HDAC8 2857/4885TGM2 312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.